Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...

Olomorasib is an investigational, selective KRAS G12C inhibitor with central nervous system activity. The phase 3 SUNRAY-01 ...

Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.

John Bridgewater, BA, MBBS, MRCP, PHD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced ...

Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and ...

Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic ...

The investigational folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) sofetabart mipitecan (LY4170156) ...

The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining ...

Matthew Gubens, MD, MS, explains how targeted therapies are moving into earlier-stage non–small cell lung cancer, while ...

1. Oliai C, Feldman DR, Slotkin E, et al. Clinical safety and efficacy of ixotatug vedotin (TORL-1-23), a claudin 6-targeted ADC, as monotherapy in germ cell tumors (GCT). Presented at: 2026 ESMO ...

The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...